Discover an insightful webinar on the latest advancements in biologics, with a special focus on antibody-drug conjugates (ADCs) and their role in transforming targeted therapies.
In this webinar, the attendees will get to learn how patient-derived models and large biobanks are driving novel target discovery, therapeutic evaluation and biomarker discovery, all aimed at improving clinical outcomes and reducing off-target effects. The expert speaker will explore the seamless generation of biologics, including antibodies, ADCs, bispecifics and peptides, backed by comprehensive in vitro and in vivo efficacy testing.
Real-world case studies will showcase how an integrated platform can help streamline drug development, from target discovery to clinical translation, and offer flexible, customizable solutions to meet specific project needs.
By attending this webinar, attendees will discover how to:
- Leverage patient-derived models for novel target discovery and biomarker identification
- Generate and optimize biologics for biochemical characterization and efficacy testing
- Utilize flexible services to accelerate drug development pipelines
Register for this webinar today to learn how to enhance biologics and ADC development programs with cutting-edge technologies and transform the development of targeted therapies.
Speaker
Peng Wang, PhD, Executive Director, Scientific Operations, Crown Bioscience
Peng Wang is responsible for cell line construction, organoid development, in vitro assays and antibody discovery at Crown Bioscience. Dr. Wang holds a PhD in Biological Sciences from the University of Delaware and completed a postdoctoral fellowship in Immunology at the University of Pennsylvania’s Perelman School of Medicine.
Dr. Wang formerly worked at Roche (China) and WuXi AppTec, with over 15 years of experience in biomedical research and drug development.
Message PresenterWho Should Attend?
This webinar will appeal to professionals from the pharmaceutical and biotech industries as well as the following:
- Researchers, R&D professionals and Scientists working in biologics and ADC development
- Professionals focused on oncology, immunotherapy and targeted therapies
- Drug discovery and preclinical development teams
- Translational Medicine Specialists
What You Will Learn
Attendees will learn about:
- Exploring and validating breakthrough targets using patient-derived models, with access to expansive collections for robust therapeutic evaluation and biomarker discovery
- Effortlessly generating novel biologics, including antibodies, bispecifics, ADCs and peptides, and ensuring success with comprehensive in vitro and in vivo biochemical characterization and efficacy testing
- How patient-derived models and large biobanks are driving novel target discovery
Xtalks Partner
Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, operates globally as a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. Crown Bioscience exclusively offers preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, it has developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, Crown Bioscience’s subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Crown Bioscience is focused on helping customers develop novel therapies aimed to ensure patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 12 facilities across the US, Europe, and Asia.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account